The Gut Microbiome as a Catalyst and Emerging Therapeutic Target for Parkinson’s Disease: A Comprehensive Update

• Published in: Biomedicines Vol. 12; no. 8; p. 1738
• Main Authors: Kerstens, Rebecca, Joyce, Paul
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.08.2024; MDPI
• Subjects: Brain research; Care and treatment; Catalysts; Communication; Constipation; Diagnosis; Disease; Dysbacteriosis; Fatty acids; Health aspects; Immune system; Intestinal microflora; Medical treatment; Metabolism; Metabolites; microbial therapies; microbiome therapeutics; Microbiomes; Microbiota; Microbiota (Symbiotic organisms); Nervous system; Neurodegenerative diseases; Parkinson's disease; Pathogenesis; Pathogens; personalised medicine; prebiotics; probiotics; Review; Therapeutic targets; Australia; microbial therapies; microbiome therapeutics; microbiota; personalised medicine; prebiotics; probiotics
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12081738

Parkinson’s Disease is the second most prevalent neurological disorder globally, and its cause is still largely unknown. Likewise, there is no cure, and existing treatments do little more than subdue symptoms before becoming ineffective. It is increasingly important to understand the factors contributing to Parkinson’s Disease aetiology so that new and more effective pharmacotherapies can be established. In recent years, there has been an emergence of research linking gut dysbiosis to Parkinson’s Disease via the gut–brain axis. Advancements in microbial profiling have led to characterisation of a Parkinson’s-specific microbial signature, where novel treatments that leverage and correct gut dysbiosis are beginning to emerge for the safe and effective treatment of Parkinson’s Disease. Preliminary clinical studies investigating microbiome-targeted therapeutics for Parkinson’s Disease have revealed promising outcomes, and as such, the aim of this review is to provide a timely and comprehensive update of the most recent advances in this field. Faecal microbiota transplantation has emerged as a novel and potential frontrunner for microbial-based therapies due to their efficacy in alleviating Parkinson’s Disease symptomology through modulation of the gut–brain axis. However, more rigorous clinical investigation, along with technological advancements in diagnostic and in vitro testing tools, are critically required to facilitate the widespread clinical translation of microbiome-targeting Parkinson’s Disease therapeutics.